[go: up one dir, main page]

WO2001040493A3 - Schizophrenia associated gene, proteins and biallelic markers - Google Patents

Schizophrenia associated gene, proteins and biallelic markers Download PDF

Info

Publication number
WO2001040493A3
WO2001040493A3 PCT/IB2000/001507 IB0001507W WO0140493A3 WO 2001040493 A3 WO2001040493 A3 WO 2001040493A3 IB 0001507 W IB0001507 W IB 0001507W WO 0140493 A3 WO0140493 A3 WO 0140493A3
Authority
WO
WIPO (PCT)
Prior art keywords
biallelic markers
proteins
schizophrenia
associated gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001507
Other languages
French (fr)
Other versions
WO2001040493A2 (en
Inventor
Daniel Cohen
Marta Blumenfeld
Ilya Chumakov
Lydie Bougueleret
Laurent Essioux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to CA002388205A priority Critical patent/CA2388205A1/en
Priority to AU76808/00A priority patent/AU7680800A/en
Priority to EP00966375A priority patent/EP1242606A2/en
Publication of WO2001040493A2 publication Critical patent/WO2001040493A2/en
Anticipated expiration legal-status Critical
Publication of WO2001040493A3 publication Critical patent/WO2001040493A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention concerns the human g35030 gene, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
PCT/IB2000/001507 1999-11-30 2000-10-04 Schizophrenia associated gene, proteins and biallelic markers Ceased WO2001040493A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002388205A CA2388205A1 (en) 1999-11-30 2000-10-04 Schizophrenia associated gene, proteins and biallelic markers
AU76808/00A AU7680800A (en) 1999-11-30 2000-10-04 Schizophrenia associated gene, proteins and biallelic markers
EP00966375A EP1242606A2 (en) 1999-11-30 2000-10-04 Schizophrenia associated gene, proteins and biallelic markers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16808899P 1999-11-30 1999-11-30
US60/168,088 1999-11-30

Publications (2)

Publication Number Publication Date
WO2001040493A2 WO2001040493A2 (en) 2001-06-07
WO2001040493A3 true WO2001040493A3 (en) 2002-07-18

Family

ID=22610070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001507 Ceased WO2001040493A2 (en) 1999-11-30 2000-10-04 Schizophrenia associated gene, proteins and biallelic markers

Country Status (4)

Country Link
EP (1) EP1242606A2 (en)
AU (1) AU7680800A (en)
CA (1) CA2388205A1 (en)
WO (1) WO2001040493A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932042B1 (en) 2010-10-13 2011-04-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature
CN113234813A (en) * 2021-06-29 2021-08-10 山西医科大学第一医院 Molecular marker of early-onset schizophrenia and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011222A1 (en) * 1996-09-13 1998-03-19 The Mount Sinai School Of Medicine Of The City University Of New York Screening methods for compounds useful in the treatment of schizophrenia
WO2000022122A2 (en) * 1998-10-13 2000-04-20 Genset Genes, proteins and biallelic markers related to central nervous system disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011222A1 (en) * 1996-09-13 1998-03-19 The Mount Sinai School Of Medicine Of The City University Of New York Screening methods for compounds useful in the treatment of schizophrenia
WO2000022122A2 (en) * 1998-10-13 2000-04-20 Genset Genes, proteins and biallelic markers related to central nervous system disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOUIN J-L ET AL: "SCHIZOPHRENIA SUSCEPTIBILITY LOCI ON CHROMOSOMES 13Q32 AND 8P21", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 1, September 1998 (1998-09-01), pages 70 - 73, XP000944108, ISSN: 1061-4036 *
DATABASE EMBL EBI; 12 July 1999 (1999-07-12), BIRREN ET AL.: "Homo sapiens clone RP11-45E4", XP002176242 *
DETERA-WADLEIGH S D ET AL: "A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 10, 11 May 1999 (1999-05-11), pages 5604 - 5609, XP002134450, ISSN: 0027-8424 *
KRUGLYAK L: "THE USE OF A GENETIC MAP OF BIALLELIC MARKERS IN LINKAGE STUDIES", NATURE GENETICS, NEW YORK, NY, US, vol. 17, no. 1, 1 September 1997 (1997-09-01), pages 22 - 24, XP002050647, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
EP1242606A2 (en) 2002-09-25
WO2001040493A2 (en) 2001-06-07
CA2388205A1 (en) 2001-06-07
AU7680800A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
WO2003029421A3 (en) Regulated breast cancer genes
WO2000050639A3 (en) Gene sequence variations with utility in determining the treatment of disease
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2004006838A3 (en) Novel kinases
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO1999055858A3 (en) Human nucleic acid sequences obtained from pancreas tumor tissue
WO2001000661A3 (en) Carnitine carrier related protein-1
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2003040331A3 (en) Prostate cancer genes
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO2001004349A3 (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
WO2001040493A3 (en) Schizophrenia associated gene, proteins and biallelic markers
WO2003054167A3 (en) Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
WO2003016485A3 (en) Full-length serine protein kinase in brain and pancreas
WO2003050303A3 (en) Biallelic markers of d-amino acid oxidase and uses thereof
WO2005085473A3 (en) Polymorphisms in the epidermal growth factor receptor gene promoter
IL156073A0 (en) Ion-channel polypeptide and gene, its preparation and use
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2008052016A3 (en) The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease
WO2000058509A3 (en) Prostate cancer associated human fibronectin gene and biallelic markers
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
WO2005014804A3 (en) Ubiquitin-specific protease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 76808/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2388205

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000966375

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000966375

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000966375

Country of ref document: EP